No Data
No Data
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $45
Wedbush Raises Viridian Therapeutics' Price Target to $45 From $42, Maintains Outperform Rating
Viridian Therapeutics Analyst Ratings
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $44
Buy Rating Affirmed for Viridian Therapeutics Following Positive THRIVE Study Results and Strong Market Potential for Veli
Express News | Viridian Therapeutics Inc : RBC Raises Target Price to $44 From $35